Workflow
MASH 飞轮
icon
Search documents
福瑞股份(300049):双重利好叠加,看好公司设备前景
Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company is expected to benefit from dual positive factors, particularly in the demand for its equipment following the approval of the MASH clinical trial [6] - The Fibroscan technology is anticipated to gain further clinical significance, establishing itself as a gold standard in non-invasive testing [6] - The successful clinical trial results of the company's affiliate, Theraclion, for its Sonovein treatment are expected to enhance its commercial prospects in the varicose vein market [6] Financial Data and Profit Forecast - Total revenue projections are as follows: - 2024: 1,349 million - 2025: 1,677 million (24.3% YoY growth) - 2026: 2,063 million (23.0% YoY growth) - 2027: 2,506 million (21.4% YoY growth) [5] - Net profit forecasts are: - 2025: 210 million (85.4% YoY growth) - 2026: 313 million (49.1% YoY growth) - 2027: 426 million (35.9% YoY growth) [5] - Earnings per share (EPS) estimates are: - 2025: 0.79 - 2026: 1.18 - 2027: 1.61 [5] - The company's return on equity (ROE) is projected to improve from 10.7% in 2025 to 17.5% in 2027 [5]